CD9P-1 Peptide Fragments Targeting CD151 for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-angiogenic treatments for cancers and tumors, such as those targeting VEGF or CD9P-1, are inefficient and often cause harmful secondary effects, necessitating the development of alternative therapies with enhanced efficacy and reduced toxicity.
Innovation Solution
The use of specific peptides, P3 and P4, which are fragments of the CD9P-1 protein, that selectively target and degrade CD151, thereby inhibiting angiogenesis without affecting CD9 or CD9P-1 levels, and can be used alone or in combination with chemotherapeutic agents like cisplatin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-angiogenic treatments (such as those targeting VEGF or CD9P-1) are used, then angiogenesis is inhibited, but harmful secondary effects occur and efficiency is insufficient
Solution Approach 1:
The patent segments the CD9P-1 protein into specific functional fragments (168A-T2 and its derivatives) that retain anti-angiogenic activity while removing portions responsible for harmful effects. This segmentation allows selective targeting of angiogenesis pathways without the systemic side effects of full-length protein or non-specific inhibitors.
Solution Approach 2:
The invention applies local quality by designing peptides with specific sequences (such as P3: GNYYCSVTPWVKS and P4: IHSKPVFITVKMDVLNA) that target particular molecular interactions in the angiogenesis pathway. These localized sequence modifications enable precise biological activity while minimizing off-target effects.
2Reliability
If polypeptide fragments (168A-T2) are used to target CD9P-1, then anti-angiogenic activity is enhanced, but specificity must be maintained to avoid affecting other tetraspanins
Solution Approach 1:
The patent divides the 168A-T2 polypeptide into smaller, defined peptide fragments with specific amino acid sequences. This segmentation creates molecules small enough to achieve high specificity for CD9P-1 while large enough to maintain stable structural conformation required for biological activity.
Solution Approach 2:
The invention modifies physical-chemical parameters of the peptide fragments, including molecular weight, amino acid composition, and structural conformation, to optimize both specificity for CD9P-1 and potency of anti-angiogenic activity. Specific sequence parameters (such as disulfide bridge positions) are carefully controlled.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to specific polypeptides having anti-angiogenic activity and their use for treating cancer.